These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Diagnostic controversies: is CBD part of the "pick complex"? Kertesz A; Munoz DG Adv Neurol; 2000; 82():223-31. PubMed ID: 10624486 [No Abstract] [Full Text] [Related]
4. Defining neurodegenerative diseases. Williams A BMJ; 2002 Jun; 324(7352):1465-6. PubMed ID: 12077015 [No Abstract] [Full Text] [Related]
5. Hazards of Neurological Nomenclature: Observations From Neurodevelopmental and Neurodegenerative Disorders. Desikan RS; Barkovich AJ JAMA Neurol; 2017 Oct; 74(10):1165-1166. PubMed ID: 28806439 [No Abstract] [Full Text] [Related]
6. Maillard reaction versus other nonenzymatic modifications in neurodegenerative processes. Pamplona R; Ilieva E; Ayala V; Bellmunt MJ; Cacabelos D; Dalfo E; Ferrer I; Portero-Otin M Ann N Y Acad Sci; 2008 Apr; 1126():315-9. PubMed ID: 18079479 [TBL] [Abstract][Full Text] [Related]
7. Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies. Chalmers KA; Love S J Neuropathol Exp Neurol; 2007 Nov; 66(11):1019-26. PubMed ID: 17984683 [TBL] [Abstract][Full Text] [Related]
9. Primary progressive aphasia as the initial manifestation of corticobasal degeneration. A "three in one " syndrome? Ioannides P; Karacostas D; Hatzipantazi M; Ioannis M Funct Neurol; 2005; 20(3):135-7. PubMed ID: 16324238 [TBL] [Abstract][Full Text] [Related]
11. Global democratic consensus on neuropathological disease criteria. Achim C; Auer R; Bergeron C; Cardozo A; Deprez M; de Vos R; Duyckaerts C; Egensperger R; Esiri M; Frosch MP; Giannini C; Goebel HH; Graeber MB; Graham DI; Gray F; Haltia M; Hashizume Y; Ikeda K; Ironside JW; Kreutzberg GW; Lantos P; Lowe J; Ludwin S; Matsumoto Y; Olsson Y; Sasaki A; Scheithauer BW; Takahashi H; Tolnay M; Trojanowski JQ; Troost D; de F Webster H Lancet Neurol; 2002 Oct; 1(6):340. PubMed ID: 12849392 [No Abstract] [Full Text] [Related]
12. Axonal transport defects: a common theme in neurodegenerative diseases. Roy S; Zhang B; Lee VM; Trojanowski JQ Acta Neuropathol; 2005 Jan; 109(1):5-13. PubMed ID: 15645263 [TBL] [Abstract][Full Text] [Related]
13. Natural history of Type A Niemann-Pick disease: possible endpoints for therapeutic trials. McGovern MM; Aron A; Brodie SE; Desnick RJ; Wasserstein MP Neurology; 2006 Jan; 66(2):228-32. PubMed ID: 16434659 [TBL] [Abstract][Full Text] [Related]
14. Depressive disorders in Parkinson's disease may be due to a shared immune-mediated neurodegenerative process. Kummer A; Teixeira AL Med Hypotheses; 2008; 70(1):201-2. PubMed ID: 17881136 [No Abstract] [Full Text] [Related]
15. Frontotemporal dementia with Pick-type histology associated with Q336R mutation in the tau gene. Pickering-Brown SM; Baker M; Nonaka T; Ikeda K; Sharma S; Mackenzie J; Simpson SA; Moore JW; Snowden JS; de Silva R; Revesz T; Hasegawa M; Hutton M; Mann DM Brain; 2004 Jun; 127(Pt 6):1415-26. PubMed ID: 15047590 [TBL] [Abstract][Full Text] [Related]
19. Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Cummings JL; Zhong K Nat Rev Drug Discov; 2006 Jan; 5(1):64-74. PubMed ID: 16485346 [TBL] [Abstract][Full Text] [Related]
20. Immunolocalization of 14-3-3 isoforms in brains with Pick body disease. Umahara T; Uchihara T; Tsuchiya K; Nakamura A; Ikeda K; Iwamoto T; Takasaki M Neurosci Lett; 2004 Nov; 371(2-3):215-9. PubMed ID: 15519760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]